Login to Your Account



GW broadens Epidiolex phase III work in third rare epilepsy indication

By Jennifer Boggs
Managing Editor

Monday, April 11, 2016

Following a positive readout last month for a phase III trial in Dravet syndrome, GW Pharmaceuticals plc is keeping the momentum going, launching late-stage testing of Epidiolex in another rare epilepsy indication and looking ahead to what could be an exciting 2016.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription